Transparency In Alzheimer’s: AdComm Expected On Regular Approval For Eisai/Biogen’s Leqembi

 
• By Sue Sutter
  
Squeegee on window
An adcomm would provide a clearer picture of the FDA's review of the lecanemab sBLA. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers